Detectie van het mammacarcinoom met behulp van een innovatief beeldvormingssysteem en folaat-FITC bij patiënten met borstkanker.
- Conditions
- Breast cancer.
- Registration Number
- NL-OMON28074
- Lead Sponsor
- niversity Medical Center Groningen (UMCG), Department of Surgery.
- Brief Summary
1. Hartmann LC, Keeney GL, Lingle WL et al. Folate receptor overexpression is associated with poor outcome in breast cancer. Int J Cancer 2007; 121:938-942.<br> 2. Sega EI, Low PS. Tumor detection using folate receptor-targeted imaging agents. Cancer Metastasis Rev 2008; 27:655-664.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 10
Inclusion Criteria
Women above the age of 21 who have biopsy-proven stage I-II breast cancer and who are planning to undergo lumpectomy as a treatment for their disease. Furthermore, folate receptor (FR) expression of the tumour must be strong (¡Ý2+), as determined by immunohistochemistry prior to surgery.
Exclusion Criteria
1. Refusal of the patient to be included in the study;
2. Pregnant or breast-feeding;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The main endpoint of this feasibility study is the intra-operative detection rate of breast carcinoma by a folate-FITC enhanced optical imaging device.
- Secondary Outcome Measures
Name Time Method